1. Marketing Group I Presentation By Anawat Pinisakul Myat Htay Kyi Salaya Phunsiri

2. Presentation Outline b b Introduction HIV/AIDS patients b b Marketing Aspects Cost of drug GDP VS Drug Cost HIV in Thailand Drug production approximation b b Conclusions and Recommendations

4. Estimated Number of People Estimated Number of Infected People in the World North AmericaOceania Latin America Sub-Saharan Africa Caribbean Eastern Europe SE Mediterranean Northeast Asia Southeast AsiaWestern Europe Geographic Region

6. Cost of Drug b Protease inhibitors cost $6,000-$8,000 per year b Bulk-purchase In Uruguay, two-third of the quoted pricesIn Uruguay, two-third of the quoted prices

7. Total cost implication of providing anti-retroviral therapy Estimated Cost ($billion) North America Western Europe Oceania Latin America Sub-Saharan Africa Caribbean Eastern Europe SE Mediterranean Northeast Asia Southeast Asia

8. GDP VS Drug Cost

9. Distribution of reported AIDS cases by year of diagnosis in Thailand, 1984-1999

10. Percentage of reported AIDS cases by risk factor, Thailand, September 1984 – 31 May 2000

11. Distribution of AIDS cases by occupation and sex September 1984 - April 2000

12. Average wage by industry in Thailand b Cost of ritonavir = US$8,308 per year

13. Drug production approximation b Ritonavir b Dosage = 600 mg per person (twice a day) = 1,200 mg/day per person = 438 g/yr person b Estimated and reported case of AIDS = 470,000 and 144,250, respectively b Reported case is only 30% of estimated

14. Drug Production Approximation b 1.3 million of infected HIV estimated by the year 2000 b 390,000 reported HIV infected b 10% die because of AIDS b 351,000 Survived HIV infected to be treated b Assume, 50% of surviving HIV infected can consume drug (175,500 persons)

15. Drug production approximation b 10 types of drugs b 10% of patients use Ritonavir b Production for 17,550 HIV infected persons b Ritonavir production = 7,690 kg/yr

16. Conclusions and Recommendations b Consideration Number of HIV patientsNumber of HIV patients Income of populationIncome of population Type of drugType of drug Government and private sectorGovernment and private sector b ARV therapy does appear affordable and cost- effective in high-income countries

17. Conclusions and Recommendations b Thailand is the second largest HIV infected population b Low GDP b Thais cannot afford antiretroviral therapy